AnaptysBio Shares Rise After Q2 Revenue Beats Analyst Estimates

Shares of AnaptysBio Inc. (ANAB) rose 3.8% in after-hours trading on Monday after the biotechnology company reported second-quarter revenue that significantly exceeded Wall Street expectations.

Revenue Beat Drives Gains

For the quarter ended June 30, 2026, the San Diego-based company posted revenue of $27.5 million, according to its financial results announcement. This figure surpassed analyst consensus estimates of approximately $20 million by more than 36%.

AnaptysBio's business model centers on managing financial collaborations for its partnered therapies. These include Jemperli, developed with Tesaro (a GSK company), and Quimilza (imsidolimab), partnered with Vanda Pharmaceuticals.

Outlook and Key Catalysts

Ad

In the earnings release, CEO Daniel Faga highlighted an optimistic outlook, pointing to "a pipeline of near-term value catalysts" for the company. Management outlined several key developments that investors are watching:

• Continued acceleration of Jemperli sales outside the United States.
• An anticipated U.S. Food and Drug Administration (FDA) approval of Jemperli as a monotherapy for a specific type of neoadjuvant rectal cancer.
• An expected judgment in ongoing litigation with GSK and Tesaro.
• A potential FDA approval for Quimilza in treating Generalized Pustular Psoriasis (GPP), anticipated in December 2026.

Market Context

The after-hours stock movement followed a positive regular session for the broader market, where Wall Street indices surged, led by gains in technology shares. AnaptysBio's strong financial report provided a company-specific driver for its stock performance.